Cargando…
Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study
BACKGROUND: This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19–9 [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of f...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466830/ https://www.ncbi.nlm.nih.gov/pubmed/37649021 http://dx.doi.org/10.1186/s12885-023-11312-4 |
_version_ | 1785098977684750336 |
---|---|
author | Huang, Jian Xiao, Yi Zhou, Yubin Deng, Huiyin Yuan, Zihao Dong, Longyan Lan, Jun Li, Xiane Liu, Gaijiao Hu, Hao Huang, Shaohong Yang, Xiongwen |
author_facet | Huang, Jian Xiao, Yi Zhou, Yubin Deng, Huiyin Yuan, Zihao Dong, Longyan Lan, Jun Li, Xiane Liu, Gaijiao Hu, Hao Huang, Shaohong Yang, Xiongwen |
author_sort | Huang, Jian |
collection | PubMed |
description | BACKGROUND: This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19–9 [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of first-line immunotherapy in patients with advanced non-small cell lung cancer. METHODS: This multicenter retrospective study evaluated patients who received first-line immunotherapy between July 2017 and July 2022. The endpoints were progression-free survival (PFS) and overall survival (OS), as defined by the Response Evaluation Criteria in Solid Tumors version 1.1. We divided the patients into three groups based on STM levels: Group A ≥ threefold upper limit of normal, threefold upper limit of normal > Group B > upper limit of normal, and Group C ≤ upper limit of normal. RESULTS: In total, 716 patients were included in this study. In Cox proportional hazards analyses, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung adenocarcinoma (LUAD). Except for CA19-9 level, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung squamous carcinoma (LUSC). Except for CEA and CA19-9 levels, the levels in Group A were independently associated with inferior PFS and OS in patients with LUAD and LUSC. CONCLUSIONS: Serum CEA, NSE, CYFRA21-1, and CA125 levels can predict PFS and OS in patients with LUAD and LUSC, and serum CA19-9 levels can predict PFS and OS in patients with LUAD. The higher the serum NSE, CYFRA21-1, and CA125 levels, the worse the PFS and OS in patients with LUAD and LUSC. In addition, the higher the serum CA19-9 level, the worse the OS in patients with LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11312-4. |
format | Online Article Text |
id | pubmed-10466830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104668302023-08-31 Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study Huang, Jian Xiao, Yi Zhou, Yubin Deng, Huiyin Yuan, Zihao Dong, Longyan Lan, Jun Li, Xiane Liu, Gaijiao Hu, Hao Huang, Shaohong Yang, Xiongwen BMC Cancer Research BACKGROUND: This study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19–9 [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of first-line immunotherapy in patients with advanced non-small cell lung cancer. METHODS: This multicenter retrospective study evaluated patients who received first-line immunotherapy between July 2017 and July 2022. The endpoints were progression-free survival (PFS) and overall survival (OS), as defined by the Response Evaluation Criteria in Solid Tumors version 1.1. We divided the patients into three groups based on STM levels: Group A ≥ threefold upper limit of normal, threefold upper limit of normal > Group B > upper limit of normal, and Group C ≤ upper limit of normal. RESULTS: In total, 716 patients were included in this study. In Cox proportional hazards analyses, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung adenocarcinoma (LUAD). Except for CA19-9 level, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung squamous carcinoma (LUSC). Except for CEA and CA19-9 levels, the levels in Group A were independently associated with inferior PFS and OS in patients with LUAD and LUSC. CONCLUSIONS: Serum CEA, NSE, CYFRA21-1, and CA125 levels can predict PFS and OS in patients with LUAD and LUSC, and serum CA19-9 levels can predict PFS and OS in patients with LUAD. The higher the serum NSE, CYFRA21-1, and CA125 levels, the worse the PFS and OS in patients with LUAD and LUSC. In addition, the higher the serum CA19-9 level, the worse the OS in patients with LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11312-4. BioMed Central 2023-08-30 /pmc/articles/PMC10466830/ /pubmed/37649021 http://dx.doi.org/10.1186/s12885-023-11312-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Huang, Jian Xiao, Yi Zhou, Yubin Deng, Huiyin Yuan, Zihao Dong, Longyan Lan, Jun Li, Xiane Liu, Gaijiao Hu, Hao Huang, Shaohong Yang, Xiongwen Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
title | Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
title_full | Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
title_fullStr | Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
title_full_unstemmed | Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
title_short | Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
title_sort | baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466830/ https://www.ncbi.nlm.nih.gov/pubmed/37649021 http://dx.doi.org/10.1186/s12885-023-11312-4 |
work_keys_str_mv | AT huangjian baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT xiaoyi baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT zhouyubin baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT denghuiyin baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT yuanzihao baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT donglongyan baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT lanjun baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT lixiane baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT liugaijiao baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT huhao baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT huangshaohong baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy AT yangxiongwen baselineserumtumormarkerspredictthesurvivalofpatientswithadvancednonsmallcelllungcancerreceivingfirstlineimmunotherapyamulticenterretrospectivestudy |